Literature DB >> 28253224

Malignant Mesothelioma Mortality - United States, 1999-2015.

Jacek M Mazurek, Girija Syamlal, John M Wood, Scott A Hendricks, Ainsley Weston.   

Abstract

Malignant mesothelioma is a neoplasm associated with occupational and environmental inhalation exposure to asbestos* fibers and other elongate mineral particles (EMPs) (1-3). Patients have a median survival of approximately 1 year from the time of diagnosis (1). The latency period from first causative exposure to malignant mesothelioma development typically ranges from 20 to 40 years but can be as long as 71 years (2,3). Hazardous occupational exposures to asbestos fibers and other EMPs have occurred in a variety of industrial operations, including mining and milling, manufacturing, shipbuilding and repair, and construction (3). Current exposures to commercial asbestos in the United States occur predominantly during maintenance operations and remediation of older buildings containing asbestos (3,4). To update information on malignant mesothelioma mortality (5), CDC analyzed annual multiple cause-of-death records† for 1999-2015, the most recent years for which complete data are available. During 1999-2015, a total of 45,221 deaths with malignant mesothelioma mentioned on the death certificate as the underlying or contributing cause of death were reported in the United States, increasing from 2,479 deaths in 1999 to 2,597 in 2015 (in the same time period the age-adjusted death rates§ decreased from 13.96 per million in 1999 to 10.93 in 2015). Malignant mesothelioma deaths increased for persons aged ≥85 years, both sexes, persons of white, black, and Asian or Pacific Islander race, and all ethnic groups. Despite regulatory actions and the decline in use of asbestos the annual number of malignant mesothelioma deaths remains substantial. The continuing occurrence of malignant mesothelioma deaths underscores the need for maintaining measures to prevent exposure to asbestos fibers and other causative EMPs and for ongoing surveillance to monitor temporal trends.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28253224      PMCID: PMC5657894          DOI: 10.15585/mmwr.mm6608a3

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


Malignant mesothelioma is a neoplasm associated with occupational and environmental inhalation exposure to asbestos* fibers and other elongate mineral particles (EMPs) (–). Patients have a median survival of approximately 1 year from the time of diagnosis (). The latency period from first causative exposure to malignant mesothelioma development typically ranges from 20 to 40 years but can be as long as 71 years (,). Hazardous occupational exposures to asbestos fibers and other EMPs have occurred in a variety of industrial operations, including mining and milling, manufacturing, shipbuilding and repair, and construction (). Current exposures to commercial asbestos in the United States occur predominantly during maintenance operations and remediation of older buildings containing asbestos (,). To update information on malignant mesothelioma mortality (), CDC analyzed annual multiple cause-of-death records for 1999–2015, the most recent years for which complete data are available. During 1999–2015, a total of 45,221 deaths with malignant mesothelioma mentioned on the death certificate as the underlying or contributing cause of death were reported in the United States, increasing from 2,479 deaths in 1999 to 2,597 in 2015 (in the same time period the age-adjusted death rates decreased from 13.96 per million in 1999 to 10.93 in 2015). Malignant mesothelioma deaths increased for persons aged ≥85 years, both sexes, persons of white, black, and Asian or Pacific Islander race, and all ethnic groups. Despite regulatory actions and the decline in use of asbestos the annual number of malignant mesothelioma deaths remains substantial. The continuing occurrence of malignant mesothelioma deaths underscores the need for maintaining measures to prevent exposure to asbestos fibers and other causative EMPs and for ongoing surveillance to monitor temporal trends. For this report, malignant mesothelioma deaths during 1999–2015 were identified from death certificates and included deaths for which International Classification of Diseases (ICD), 10th Revision codes for malignant mesothelioma were listed as either the underlying or contributing cause of death in the multiple cause-of-death mortality data. The analysis was restricted to deaths of persons aged ≥25 years, as they were more likely to have been occupationally exposed than were younger decedents. Age-adjusted death rates per 1 million persons aged ≥25 years by demographics, neoplasm anatomical site, and year were calculated using the 2000 U.S. Census standard population estimate. Industry and occupation information was available from death certificates for decedents reported from 23 states for 1999, 2003, 2004, and 2007, and was coded** using the U.S. Census 2000 Industry and Occupation Classification System. Proportionate mortality ratios (PMRs) for malignant mesothelioma by industry and occupation were calculated. Confidence intervals (CIs) were calculated assuming Poisson distribution of the data. During 1999–2015, a total of 45,221 deaths with malignant mesothelioma mentioned on the death certificate as the underlying or contributing cause of death among persons aged ≥25 years were reported in the United States; 16,914 (37.4%) occurred among persons aged 75–84 years, 36,093 (79.8%) occurred among males, 42,778 (94.6%) among whites, and 43,316 (95.8%) among non-Hispanics (Table 1). Malignant mesothelioma was classified as mesothelioma of pleura (3,351; 7.4%), peritoneum (1,854; 4.1%), pericardium (74; 0.2%), other anatomic site (5,280; 11.7%), and unspecified anatomic site (35,068; 77.5%). Among 42,470 (93.9%) decedents, malignant mesothelioma was coded as the underlying cause of death.
TABLE 1

Malignant mesothelioma deaths and age-adjusted rates* among decedents aged ≥25 years, by selected characteristics — United States, 1999–2015

CharacteristicsNo. of deathsDeath rate
Total
45,221
13.10
Underlying cause
42,470
12.30
Age group (yrs)§
  25–34
138
0.20
  35–44
544
0.75
  45–54
1,936
2.69
  55–64
6,237
11.22
  65–74
12,985
36.31
  75–84
16,914
76.28
  ≥85
6,467
74.46
Sex
  Male
36,093
24.94
  Female
9,128
4.65
Race
  White
42,778
14.25
  Black or African American
1,870
5.84
  Asian or Pacific Islander
440
3.52
  American Indian or Alaska  Native
133
5.96
Ethnicity
Hispanic
1,815
7.38
Non-Hispanic
43,316
13.46
Unknown
90

Anatomic site
  Pleura
3,351
0.98
  Peritoneum
1,854
0.51
  Pericardium
74
0.01
  Other
5,280
1.52
  Unspecified
35,068
10.14
Year
  1999
2,479
13.96
  2000
2,529
14.16
  2001
2,504
13.77
  2002
2,570
13.92
  2003
2,621
13.95
  2004
2,656
13.94
  2005
2,701
13.93
  2006
2,586
13.19
  2007
2,603
12.98
  2008
2,706
13.26
  2009
2,752
13.20
  2010
2,744
13.10
  2011
2,829
13.16
  2012
2,873
12.97
  2013
2,686
11.80
  2014
2,785
11.98
  2015
2,597
10.93
  P-value**0.001<0.001

* Age-adjusted death rates per 1 million persons calculated using the 2000 Standard population.

† Underlying cause of death is defined as “the disease or injury which initiated the chain of morbid events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury.”

§ Age-specific death rates per 1 million persons.

¶ The sum of anatomic site totals (45,627) is greater than the total number of deaths (45,221) because some decedents have more than one site listed on their death certificate.

** For 1999–2015, linear time trend was examined using a first-order autoregressive linear regression model to account for the serial correlation.

* Age-adjusted death rates per 1 million persons calculated using the 2000 Standard population. † Underlying cause of death is defined as “the disease or injury which initiated the chain of morbid events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury.” § Age-specific death rates per 1 million persons. ¶ The sum of anatomic site totals (45,627) is greater than the total number of deaths (45,221) because some decedents have more than one site listed on their death certificate. ** For 1999–2015, linear time trend was examined using a first-order autoregressive linear regression model to account for the serial correlation. During 1999–2015, the annual number of malignant mesothelioma deaths increased 4.8% overall, from 2,479 in 1999 to 2,579 in 2015 (p-value for linear time trend <0.001). The number of malignant mesothelioma deaths increased among persons aged ≥85 years, both sexes, white, black, and Asian or Pacific Islander race, and all ethnic groups; and patients with mesothelioma of the peritoneum and unspecified anatomic site. Malignant mesothelioma deaths decreased among persons aged 35–44, 45–54, and 55–64 years, and among persons with mesothelioma of the pleura and other anatomic sites. During 1999–2015, the mesothelioma age-adjusted death rate decreased 21.7% from 13.96 per million population (1999) to 10.93 (2015) (p-value for time trend <0.001). This trend in the standardized rate is a weighted average of the trends in the age-specific rates and masks the differences in individual age groups. The age-specific death rate decreased significantly among persons 45–54 (p<0.001), 55–64 (p<0.001), and 65–74 (p<0.001) years and increased significantly among persons aged ≥85 years (p<0.001). During 1999–2015, the annualized state mesothelioma age-adjusted death rate exceeded 20 per million per year in two states: Maine (22.06) and Washington (20.10) (Figure).
FIGURE

Malignant mesothelioma annualized age-adjusted death rate* per 1 million population, by state — United States, 1999–2015

* Age-adjusted death rates were calculated by applying age-specific death rates to the 2000 U.S standard population age distribution (https://wonder.cdc.gov/wonder/help/mcd.html#Age-Adjusted Rates). In two states (Maine and Washington), the age-adjusted death rate exceeded 20 per million per year.

† Decedents aged ≥25 years for whom the International Classification of Diseases, 10th Revision codes C45.0 (mesothelioma of pleura), C45.1 (mesothelioma of peritoneum), C45.2 (mesothelioma of pericardium), C45.7 (mesothelioma of other sites), or C45.9 (mesothelioma, unspecified) were listed on death certificates were identified using CDC multiple cause-of-death data for 1999–2015.

Malignant mesothelioma annualized age-adjusted death rate* per 1 million population, by state — United States, 1999–2015 * Age-adjusted death rates were calculated by applying age-specific death rates to the 2000 U.S standard population age distribution (https://wonder.cdc.gov/wonder/help/mcd.html#Age-Adjusted Rates). In two states (Maine and Washington), the age-adjusted death rate exceeded 20 per million per year. † Decedents aged ≥25 years for whom the International Classification of Diseases, 10th Revision codes C45.0 (mesothelioma of pleura), C45.1 (mesothelioma of peritoneum), C45.2 (mesothelioma of pericardium), C45.7 (mesothelioma of other sites), or C45.9 (mesothelioma, unspecified) were listed on death certificates were identified using CDC multiple cause-of-death data for 1999–2015. Industry and occupation data were available for 1,830 (96.3%) of 1,900 malignant mesothelioma deaths that occurred in residents of 23 states during 1999, 2003, 2004, and 2007 (Table 2). Among 207 industries and 274 occupations, significantly elevated PMRs for malignant mesothelioma were found for 11 industries and 17 occupations. By industry, the highest PMRs were for ship and boat building and repairing (6.7; 95% CI = 4.3–9.9); petroleum refining (4.1; CI = 2.6–6.0); and industrial and miscellaneous chemicals (3.8; CI = 2.9–5.0). By occupation, the highest PMRs were for insulation workers (26.9; CI = 16.2–42.0); chemical technicians (4.9; CI = 2.1–9.6); and pipelayers, plumbers, pipefitters, and steamfitters (4.8; CI = 3.7–6.1).
TABLE 2

Industries and occupations with significantly elevated proportionate mortality ratios, 1,830 malignant mesothelioma decedents aged ≥25 years — 23 states,* 1999, 2003, 2004, and 2007

CharacteristicNo. of deathsPMR (95% CI)
Industry
   Ship and boat building
24
6.7 (4.3–9.9)
   Petroleum refining
25
4.1 (2.6–6.0)
   Industrial and miscellaneous chemicals
58
3.8 (2.9–5.0)
   Labor unions
7
3.7 (1.5–7.6)
   Miscellaneous nonmetallic mineral product manufacturing
5
3.6 (1.2–8.4)
   Electric and gas and other combinations
7
3.1 (1.3–6.5)
   Water transportation
12
2.3 (1.2–3.9)
   Electric power generation transmission and distribution
24
2.2 (1.4–3.3)
   U.S. Navy
11
2.0 (1.0–3.6)
   Architectural, engineering, and related services
23
1.9 (1.2–2.8)
   Construction
280
1.6 (1.4–1.8)
   Unknown
42

   All other industries
1,312

Occupation
   Insulation workers
19
26.9 (16.2–42.0)
   Chemical technicians
8
4.9 (2.1–9.6)
   Pipelayers, plumbers, pipefitters, and steamfitters
67
4.8 (3.7–6.1)
   Chemical engineers
12
4.0 (2.1–7.1)
   Sheet metal workers
17
3.5 (2.0–5.5)
   Sailors and marine oilers
5
3.4 (1.1–8.0)
   Structural iron and steel workers
10
3.3 (1.6–6.0)
   Millwrights
14
3.1 (1.7–5.2)
   Stationary engineers and boiler operators
15
2.9 (1.6–4.8)
   Electricians
53
2.8 (2.1–3.7)
   Welding, soldering, and brazing workers
30
2.1 (1.4–3.0)
   Construction managers
37
2.0 (1.4–2.8)
   Engineers, all other
12
2.0 (1.0–3.5)
   Mechanical engineers
14
1.9 (1.0–3.2)
   First-line supervisors or managers of mechanics, installers, and repairers
27
1.8 (1.2–2.6)
   Machinists
39
1.6 (1.1–2.1)
   First-line supervisors or managers of production and operating workers
40
1.4 (1.0–2.0)
   Unknown
49

   All other occupations1,362

Abbreviations: CI = confidence interval; PMR = proportionate mortality ratio.

* Multiple cause-of-death mortality files. https://webappa.cdc.gov/ords/norms-io14.html.

† PMR is defined as the observed number of deaths with malignant mesothelioma in a specified industry/occupation, divided by the expected number of deaths with malignant mesothelioma. The expected number of deaths is the total number of deaths in industry or occupation of interest multiplied by a proportion defined as the number of malignant mesothelioma deaths in all industries and/or occupations, divided by the total number of deaths in all industries/occupations. The malignant mesothelioma PMRs were internally adjusted by five-year age groups, gender, and race. CIs were calculated assuming Poisson distribution of the data.

Abbreviations: CI = confidence interval; PMR = proportionate mortality ratio. * Multiple cause-of-death mortality files. https://webappa.cdc.gov/ords/norms-io14.html. † PMR is defined as the observed number of deaths with malignant mesothelioma in a specified industry/occupation, divided by the expected number of deaths with malignant mesothelioma. The expected number of deaths is the total number of deaths in industry or occupation of interest multiplied by a proportion defined as the number of malignant mesothelioma deaths in all industries and/or occupations, divided by the total number of deaths in all industries/occupations. The malignant mesothelioma PMRs were internally adjusted by five-year age groups, gender, and race. CIs were calculated assuming Poisson distribution of the data.

Discussion

The annual number of malignant mesothelioma deaths is increasing, particularly among persons aged ≥85 years, most likely representing exposure many years ago. However, although malignant mesothelioma deaths decreased in persons aged 35–64 years, the continuing occurrence of mesothelioma deaths among persons aged <55 years suggests ongoing occupational and environmental exposures to asbestos fibers and other causative EMPs, despite regulatory actions by the Occupational Safety and Health Administration (OSHA)*** and the Environmental Protection Agency aimed at limiting asbestos exposure. OSHA established a permissible exposure limit for asbestos of 12 fibers per cubic centimeter (f/cc) of air as an 8-hour time-weighted average in 1971. This initial permissible exposure limit was reduced to 5 f/cc in 1972, 2 f/cc in 1976, 0.2 f/cc in 1986, and 0.1 f/cc in 1994 (). Although inspection data during 1979–2003 indicated a general decline in the proportion of samples exceeding designated occupational exposure limits, 20% of air samples collected in the construction industry in 2003 for compliance purposes exceeded the OSHA permissible exposure limit. Moreover, asbestos products remain in use, and new asbestos-containing products continue to be manufactured in or imported into the United States. Although most deaths from malignant mesothelioma in the United States are the result of exposures to asbestos 20–40 years prior, new cases might result from occupational exposure to asbestos fibers during maintenance activities, demolition and remediation of existing asbestos in structures, installations, and buildings if controls are insufficient to protect workers. The OSHA asbestos standard describes engineering and work practice controls (e.g., use of wet methods, local exhaust ventilation, and vacuum cleaners equipped with high-efficiency particulate air [HEPA] filters) during asbestos handling, mixing, removal, cutting, application, and cleanup and requires the use of respiratory protection if these controls are not sufficient to reduce employee exposure to levels at or below the permissible limit. Moreover, family members of workers engaged in activities placing them at risk for asbestos exposures also have the potential for exposure to asbestos (). In addition, ongoing research is focusing on the potential nonoccupational and environmental exposures to asbestos fibers and other EMPs (e.g., erionite, a naturally occurring fibrous mineral that belongs to a group of minerals called zeolites), and nonmineral elongate particles (e.g., carbon nanotubes) to assess exposures and potential health risks (,). Among the 96.3% of deaths in 23 states for which industry and occupation were known, shipbuilding and construction industries were major contributors to malignant mesothelioma mortality (). The large number of deaths among construction workers is consistent with large number of construction workers with prior direct and indirect exposure to asbestos fibers through most of the 20th century (the construction industry accounted for 70%–80% of asbestos consumption) (). For example, direct exposure to asbestos has occurred during installation of asbestos-cement pipes, asbestos-cement sheets, architectural panels, built-up roofing, and removal of roofing felts or asbestos insulation. Workers also might have been exposed to asbestos during spraying of asbestos insulation in multistoried structures during 1958–1972 (asbestos-containing materials were banned for fireproofing/insulating in 1973) (). In addition, workers in other occupations (e.g., carpenters, electricians, pipefitters, plumbers, welders) might also have been exposed if they were present on-site during spraying activities. A review of studies projecting the number of deaths from asbestos-related malignant mesothelioma in the United States indicated that the number of deaths during 1985–2009 would range from 620 to 3,270 annually (). Based on an estimated 27.5 million workers with some exposure to asbestos during 1940–1972, a 1982 study estimated that the number of malignant mesothelioma deaths would rise to 3,060 annually by 2001–2005 (). After 2005, mortality was projected to decrease but would continue for three decades. Based on asbestos consumption and malignant mesothelioma incidence data, it was estimated that the number of mesothelioma cases among males would peak during 2000–2004 (approximately 2,000 cases) and after that period, the number of mesothelioma cases was expected to decline and return to background levels by 2055 (). The number of mesothelioma cases among females (approximately 560 in 2003) was projected to increase slightly over time. The results of the current study indicate an increase in the number of malignant mesothelioma deaths during 1999–2015. This discrepancy might be explained, in part, by the methodology of the projection studies, which were based on multiple assumptions including variations in the number of employed workers at risk, exposure levels and timing, and the linear dose–response relationship between asbestos exposure and malignant mesothelioma. Moreover, additional persons who might have been exposed to asbestos and be at risk for malignant mesothelioma (e.g., family contacts of asbestos-exposed workers, persons exposed to naturally occurring asbestos, persons exposed to asbestos in surfacing materials or as fireproofing material in buildings) were not considered (,). The findings in this report are subject to at least five limitations. First, information on exposure to asbestos or a specific work history was not available to assess the potential source of exposure. The industry and occupation listed on a death certificate might not be the industry and occupation in which the decedent's exposures occurred. Second, the state issuing a death certificate might not be the state or country in which the decedent's exposures occurred. Third, malignant mesothelioma did not have a discrete ICD code until the 10th revision of the ICD; thus, evaluation of mortality trends before 1999 was not possible. Fourth, some mesothelioma cases might not be included in this analysis because of misdiagnosis and the use of incorrect ICD-10 codes (). Finally, information on decedents’ industry and occupation was available only for selected states of residence and years, and might not be nationally representative. Despite regulatory actions and the decline in use of asbestos, the annual number of malignant mesothelioma deaths remains substantial. Effective asbestos exposure prevention strategies for employers recommended by OSHA and CDC’s National Institute for Occupational Safety and Health (https://www.cdc.gov/niosh/topics/asbestos/) are available. The continuing occurrence of malignant mesothelioma deaths underscores the need for maintaining asbestos exposure prevention efforts and for ongoing surveillance to monitor temporal trends.

What is already known about this topic?

Malignant mesothelioma is a neoplasm associated with inhalation exposure to asbestos fibers and other elongate mineral particles (EMPs). The median survival after malignant mesothelioma diagnosis is approximately 1 year. The latency period between the first exposure to asbestos fibers or other EMPs and mesothelioma development ranges from 20 to 71 years. Occupational exposure has occurred in industrial operations including mining and milling, manufacturing, shipbuilding and repair, and construction. Current occupational exposure occurs predominantly during maintenance and remediation of asbestos-containing buildings. The projected number of malignant mesothelioma deaths was expected to increase to 3,060 annually by 2001–2005, and after 2005, mortality was projected to decrease.

What is added by this report?

During 1999–2015, a total of 45,221 malignant mesothelioma deaths were reported, increasing from 2,479 (1999) to 2,597 (2015). Mesothelioma deaths increased for persons aged ≥85 years, for both sexes, persons of white, black and Asian or Pacific Islander race, and all ethnic groups. Continuing occurrence of malignant mesothelioma deaths in persons aged <55 years suggests ongoing inhalation exposure to asbestos fibers and possibly other causative EMPs.

What are the implications for public health practice?

Despite regulatory actions and decline in asbestos use, the annual number of malignant mesothelioma deaths remains substantial. Contrary to past projections, the number of malignant mesothelioma deaths has been increasing. The continuing occurrence of mesothelioma deaths, particularly among younger populations, underscores the need for maintaining efforts to prevent exposure and for ongoing surveillance to monitor temporal trends.
  8 in total

1.  The history of OSHA's asbestos rule makings and some distinctive approaches that they introduced for regulating occupational exposure to toxic substances.

Authors:  J F Martonik; E Nash; E Grossman
Journal:  AIHAJ       Date:  2001 Mar-Apr

2.  Mesothelioma from asbestos exposures: Epidemiologic patterns and impact in the United States.

Authors:  Richard A Lemen
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2016       Impact factor: 6.393

3.  Occupational exposure to asbestos: population at risk and projected mortality--1980-2030.

Authors:  W J Nicholson; G Perkel; I J Selikoff
Journal:  Am J Ind Med       Date:  1982       Impact factor: 2.214

4.  Asbestos in commercial cosmetic talcum powder as a cause of mesothelioma in women.

Authors:  Ronald E Gordon; Sean Fitzgerald; James Millette
Journal:  Int J Occup Environ Health       Date:  2014-09-03

5.  Projection of asbestos related diseases in the United States, 1985-2009. I. Cancer.

Authors:  D E Lilienfeld; J S Mandel; P Coin; L M Schuman
Journal:  Br J Ind Med       Date:  1988-05

6.  Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.

Authors:  Bertram Price; Adam Ware
Journal:  Am J Epidemiol       Date:  2004-01-15       Impact factor: 4.897

Review 7.  Latent period for malignant mesothelioma of occupational origin.

Authors:  B P Lanphear; C R Buncher
Journal:  J Occup Med       Date:  1992-07

8.  Current Research and Opportunities to Address Environmental Asbestos Exposures.

Authors:  Danielle J Carlin; Theodore C Larson; Jean C Pfau; Stephen H Gavett; Arti Shukla; Aubrey Miller; Ronald Hines
Journal:  Environ Health Perspect       Date:  2015-08       Impact factor: 9.031

  8 in total
  43 in total

Review 1.  In vitro experimental models of mesothelioma revisited.

Authors:  Anand Singh; Nathanael Pruett; Chuong D Hoang
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Personalized treatment of malignant mesothelioma-dream or reality?

Authors:  Anja C Roden
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Novel insights and recent discoveries on the genetics and pathogenesis of malignant mesothelioma.

Authors:  Yin P Hung; Lucian R Chirieac
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 4.  Landmark Trials in the Surgical Management of Mesothelioma.

Authors:  Taylor Kantor; Elliot Wakeam
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

5.  Molecular characterization of diffuse malignant peritoneal mesothelioma.

Authors:  Yin P Hung; Fei Dong; Matthew Torre; Christopher P Crum; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2020-06-05       Impact factor: 7.842

Review 6.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

Review 7.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

8.  Mouse serum exosomal proteomic signature in response to asbestos exposure.

Authors:  Phillip Munson; Ying-Wai Lam; Maximilian MacPherson; Stacie Beuschel; Arti Shukla
Journal:  J Cell Biochem       Date:  2018-04-16       Impact factor: 4.429

9.  Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.

Authors:  Lucian R Chirieac; Yin P Hung; Wai Chin Foo; Matthias D Hofer; Paul A VanderLaan; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Cancer       Date:  2019-08-07       Impact factor: 6.860

Review 10.  Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.

Authors:  Lisa Brusselmans; Lieselot Arnouts; Charissa Millevert; Joyce Vandersnickt; Jan P van Meerbeeck; Kevin Lamote
Journal:  Transl Lung Cancer Res       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.